Iguana Healthcare Management LLC Invests $1.20 Million in Catalent Inc (CTLT)
Iguana Healthcare Management LLC purchased a new position in Catalent Inc (NYSE:CTLT) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 30,000 shares of the company’s stock, valued at approximately $1,198,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Janus Henderson Group PLC purchased a new position in shares of Catalent during the second quarter worth $239,629,000. BlackRock Inc. raised its holdings in shares of Catalent by 15.2% during the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after purchasing an additional 2,316,849 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in shares of Catalent by 290.9% during the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after purchasing an additional 858,600 shares during the last quarter. AJO LP purchased a new position in shares of Catalent during the second quarter worth $26,130,000. Finally, Macquarie Group Ltd. raised its holdings in shares of Catalent by 60.2% during the second quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock worth $62,715,000 after purchasing an additional 671,429 shares during the last quarter. 99.49% of the stock is owned by institutional investors and hedge funds.
In other news, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Uwe Roehrhoff bought 7,500 shares of the company’s stock in a transaction dated Tuesday, November 21st. The stock was bought at an average price of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is currently owned by company insiders.
Several brokerages recently issued reports on CTLT. ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. BidaskClub raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Needham & Company LLC reissued a “hold” rating on shares of Catalent in a report on Monday, October 23rd. Wells Fargo & Company raised their target price on shares of Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a report on Wednesday, September 20th. Finally, Bank of America reissued a “buy” rating and set a $45.00 target price (up previously from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $44.44.
Shares of Catalent Inc (NYSE:CTLT) opened at $40.02 on Thursday. The company has a market cap of $5,253.27, a price-to-earnings ratio of 27.65, a P/E/G ratio of 2.54 and a beta of 1.41. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. Catalent Inc has a 52-week low of $25.51 and a 52-week high of $43.39.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The firm’s revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the business earned $0.16 earnings per share. equities analysts expect that Catalent Inc will post 1.46 EPS for the current year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.